Tyme Technologies Taps Eckard for Chief Scientific Affairs Post

12:56 EDT 10 Aug 2017 | Xconomy

Tyme Technologies (NASDAQ: TYME) has appointed Jonathan Eckard chief scientific affairs officer. Eckard most recently worked as chief business and strategy officer for cancer drug developer Sellas Life Sciences. New York-based Tyme’s lead drug candidate, SM-88, is in early-stage testing as a potential prostate cancer treatment.

Original Article: Tyme Technologies Taps Eckard for Chief Scientific Affairs Post


More From BioPortfolio on "Tyme Technologies Taps Eckard for Chief Scientific Affairs Post"

Quick Search

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...